Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Enanta Pharmaceuticals Inc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 101 | 1 | 112 | +12 |
| Shares | 22.1M | 1.85M | 21.2M | +945.5K (+4.7%) |
| Value | $287.0M | $24.0M | $220.0M | −$43.1M (−16.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,900,323 | $19.7M | 0.00% |
| Point72 Asset Management, L.P. | 87,190 | $903.3K | 0.00% |
| Bridgeway Capital Management, LLC | 48,000 | $497.3K | 0.01% |
| Wellington Management Group LLP | 34,751 | $360.0K | 0.00% |
| Valence8 US LP | 19,939 | $206.6K | 0.09% |
| Corton Capital Inc. | 13,116 | $135.9K | 0.07% |
| Connor, Clark & Lunn Investment Management Ltd. | 11,768 | $121.9K | 0.00% |
| Tudor Investment Corp Et Al | 10,349 | $107.2K | 0.00% |
| Aquatic Capital Management LLC | 4,000 | $41.4K | 0.00% |
| Headlands Technologies LLC | 1,322 | $13.7K | 0.00% |
| nVerses Capital, LLC | 1,200 | $12.4K | 0.01% |
| Point72 (DIFC) Ltd | 401 | $4.15K | 0.00% |
| Venturi Wealth Management, LLC | 385 | $3.99K | 0.00% |
| Smartleaf Asset Management LLC | 157 | $1.58K | 0.00% |
| Sachetta, LLC | 100 | $1.04K | 0.00% |
| Sterling Capital Management LLC | 64 | $663 | 0.00% |
| Capital Performance Advisors LLP | 63 | $653 | 0.00% |
| Voisard Asset Management Group, Inc. | 28 | $291 | 0.00% |
Sold out (6)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 45,999 | $596.6K |
| Pennant Investors, LP | 35,100 | $455.2K |
| Point72 Asia (Singapore) Pte. Ltd. | 14,326 | $185.8K |
| Cornercap Investment Counsel Inc | 13,760 | $178.5K |
| Gladius Capital Management LP | 2,620 | $34.0K |
| Innealta Capital, LLC | 16 | $208 |
Not filed for Q3 2024 yet (1)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,847,519 | $24.0M |